Evidence map›Paper›PMID 29594935›Full record

ReviewMolecular neurobiology2018

Diabetes Mellitus as a Risk Factor for Parkinson's Disease: a Molecular Point of View.

Alice Biosa, Tiago F Outeiro, Luigi Bubacco, Marco Bisaglia

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 76 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Metformin as a potential neuroprotective agent that influence Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 3 countries.

Alice BiosaMolecular Physiology and Biophysics Unit, Department of Biology, University of Padova, Padova, Italy.
Tiago F OuteiroDepartment of Experimental Neurodegeneration, University Medical Center Goettingen, Goettingen, Germany.
Luigi BubaccoMolecular Physiology and Biophysics Unit, Department of Biology, University of Padova, Padova, Italy.
Marco BisagliaMolecular Physiology and Biophysics Unit, Department of Biology, University of Padova, Padova, Italy. marco.bisaglia@unipd.it.ORCID http://orcid.org/0000-0002-3968-8418
University of Padua · ITMax Planck Institute of Experimental Medicine · DE

Funding

Federal Ministry of Education and Research (BMBF) and the EU Joint programme - Neurodegenerative Disease Research (JPND) aSynProtecItalian Ministry of Education, University and Research 2015T778JW
6 · The paper itself

Abstract

Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by elevated concentrations of glucose in the blood. The chronic hyperglycemic state accounts for most of the vascular complications associated to the disease and the prevalent mechanism proposed is related to the glycating chemistry mediated by methylglyoxal (MG), which accumulates in T2DM. In recent years, a higher risk of Parkinson's disease (PD) onset in people affected by T2DM has become evident, but the molecular mechanisms underlying the interplay between T2DM and PD are still unknown. The oxidative chemistry of dopamine and its reactivity towards the protein α-Synuclein (aS) has been associated to the pathogenesis of PD. Recently, aS has also been described to interact with MG. Interestingly, MG and the dopamine oxidation products share both structural similarity and chemical reactivity. The ability of MG to spread over the site of its production and react with aS could represent the rationale to explain the higher incidence of PD in T2DM-affected people and may open opportunities for the development of novel strategies to antagonize the raise of PD.

Indexed as

alpha-SynucleinAnimalsDiabetes Mellitus, Type 2DopamineHumansModels, BiologicalParkinson DiseaseRisk Factorsalpha-SynucleinDopamineDOPALDopamineMethylglyoxalParkinson’s diseaseType 2 diabetes mellitusα-Synuclein

Identifiers

PMID29594935
OpenAlexW2794842962

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.